|Research Studies » Multiple Sclerosis|
Patients who, as part of their routine clinical care and according to the locally approved label, are either:
• Starting fingolimod at time of study entry;
• Starting another approved DMT or started prior to study entry (within maximum 6 months); and
• Willing to provide written informed consent (patient or legal representative).